Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 2
2008 1
2009 1
2010 1
2012 1
2013 2
2014 2
2017 1
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
Østergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Gudbjornsson B, Ørnbjerg LM, Bøyesen P, Lend K, Hørslev-Petersen K, Uhlig T, Sokka T, Grondal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic MC, Aga AB, Faustini F, Parmanne P, Lorenzen T, Giovanni C, Back J, Hendricks O, Vedder D, Rannio T, Grenholm E, Ljoså MK, Brodin E, Lindegaard H, Söderbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Bay Laurbjerg T, Bakland G, Olsen IC, Haavardsholm EA, Lampa J; NORD-STAR study group. Østergaard M, et al. Among authors: heiberg ms. Ann Rheum Dis. 2023 Oct;82(10):1286-1295. doi: 10.1136/ard-2023-224116. Epub 2023 Jul 9. Ann Rheum Dis. 2023. PMID: 37423647 Clinical Trial.
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R; NORD-STAR study group. Hetland ML, et al. Among authors: heiberg ms. BMJ. 2020 Dec 2;371:m4328. doi: 10.1136/bmj.m4328. BMJ. 2020. PMID: 33268527 Free PMC article. Clinical Trial.
Rheumatology congresses post COVID-19: we cannot regress.
Nordberg LB, Vikse J, Heiberg MS, Lillejordet E, Mæhlen MT, Kristianslund EK, Provan SA, Lillegraven S. Nordberg LB, et al. Among authors: heiberg ms. Lancet Rheumatol. 2023 Jul;5(7):e370-e371. doi: 10.1016/S2665-9913(23)00153-4. Epub 2023 Jun 2. Lancet Rheumatol. 2023. PMID: 37360002 Free PMC article. No abstract available.
Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.
Lend K, Koopman FA, Lampa J, Jansen G, Hetland ML, Uhlig T, Nordström D, Nurmohamed M, Gudbjornsson B, Rudin A, Østergaard M, Heiberg MS, Sokka-Isler T, Hørslev-Petersen K, Haavardsholm EA, Grondal G, Twisk JWR, van Vollenhoven R. Lend K, et al. Among authors: heiberg ms. Arthritis Rheumatol. 2024 Mar;76(3):363-376. doi: 10.1002/art.42730. Epub 2024 Jan 18. Arthritis Rheumatol. 2024. PMID: 37846618 Clinical Trial.
[Bechterew disease--a consensus on diagnosis and treatment].
Dagfinrud H, Heiberg MS, Bakland G, Skomsvoll J, Kvien TK. Dagfinrud H, et al. Among authors: heiberg ms. Tidsskr Nor Laegeforen. 2007 Dec 13;127(24):3209-12. Tidsskr Nor Laegeforen. 2007. PMID: 18084362 Free article. Review. Norwegian.
Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial.
Lend K, van Vollenhoven RF, Lampa J, Lund Hetland M, Haavardsholm EA, Nordström D, Nurmohamed M, Gudbjornsson B, Rudin A, Østergaard M, Uhlig T, Grondal G, Hørslev-Petersen K, Heiberg MS, Sokka-Isler T, Koopman FA, Twisk JWR, van der Horst-Bruinsma I. Lend K, et al. Among authors: heiberg ms. Lancet Rheumatol. 2022 Oct;4(10):e688-e698. doi: 10.1016/S2665-9913(22)00186-2. Epub 2022 Aug 23. Lancet Rheumatol. 2022. PMID: 38265967 Clinical Trial.
Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.
Stockfelt M, Lundell AC, Hetland ML, Østergaard M, Uhlig T, Heiberg MS, Haavardsholm EA, Nurmohamed MT, Lampa J, Nordström D, Petersen KH, Gudbjornsson B, Gröndal G, Aldridge J, Andersson K, Blennow K, Zetterberg H, van Vollenhoven R, Rudin A. Stockfelt M, et al. Among authors: heiberg ms. Arthritis Res Ther. 2021 Jul 13;23(1):189. doi: 10.1186/s13075-021-02556-1. Arthritis Res Ther. 2021. PMID: 34256800 Free PMC article. Clinical Trial.
Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.
Glinatsi D, Heiberg MS, Rudin A, Nordström D, Haavardsholm EA, Gudbjornsson B, Østergaard M, Uhlig T, Grondal G, Hørslev-Petersen K, van Vollenhoven R, Hetland ML. Glinatsi D, et al. Among authors: heiberg ms. Trials. 2017 Apr 4;18(1):161. doi: 10.1186/s13063-017-1891-x. Trials. 2017. PMID: 28376912 Free PMC article. Clinical Trial.
18 results